The Cooper Companies, Inc. (NASDAQ:COO) Shares Purchased by Advisor OS LLC

Advisor OS LLC boosted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 1.9% during the 2nd quarter, Holdings Channel reports. The fund owned 14,508 shares of the medical device company’s stock after acquiring an additional 274 shares during the quarter. Advisor OS LLC’s holdings in Cooper Companies were worth $1,267,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its holdings in Cooper Companies by 1.2% during the fourth quarter. Franklin Resources Inc. now owns 3,401 shares of the medical device company’s stock worth $1,287,000 after purchasing an additional 41 shares in the last quarter. KLR Investment Advisors LLC raised its holdings in Cooper Companies by 4.3% during the fourth quarter. KLR Investment Advisors LLC now owns 1,117 shares of the medical device company’s stock worth $423,000 after purchasing an additional 46 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in Cooper Companies by 10.8% during the fourth quarter. Quadrant Capital Group LLC now owns 613 shares of the medical device company’s stock worth $232,000 after purchasing an additional 60 shares in the last quarter. Westpac Banking Corp raised its holdings in Cooper Companies by 18.8% during the fourth quarter. Westpac Banking Corp now owns 543 shares of the medical device company’s stock worth $205,000 after purchasing an additional 86 shares in the last quarter. Finally, Lincoln National Corp raised its holdings in Cooper Companies by 13.9% during the fourth quarter. Lincoln National Corp now owns 768 shares of the medical device company’s stock worth $291,000 after purchasing an additional 94 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Ratings Changes

COO has been the topic of a number of research analyst reports. Jefferies Financial Group raised shares of Cooper Companies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $107.00 to $115.00 in a report on Tuesday, July 16th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $115.00 target price (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Piper Sandler lifted their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Finally, Robert W. Baird lifted their target price on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Cooper Companies has an average rating of “Moderate Buy” and an average price target of $113.61.

Insider Buying and Selling

In related news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now directly owns 44,696 shares in the company, valued at approximately $4,714,534.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Brian G. Andrews sold 24,788 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the transaction, the chief financial officer now owns 6,614 shares of the company’s stock, valued at approximately $700,422.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the sale, the chief operating officer now directly owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Cooper Companies Stock Performance

NASDAQ:COO opened at $106.59 on Friday. The firm’s fifty day moving average price is $93.30 and its 200 day moving average price is $94.65. The Cooper Companies, Inc. has a 1-year low of $75.93 and a 1-year high of $107.82. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.99 and a quick ratio of 1.14. The firm has a market cap of $21.22 billion, a price-to-earnings ratio of 62.70, a price-to-earnings-growth ratio of 2.56 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.84 EPS. On average, sell-side analysts expect that The Cooper Companies, Inc. will post 3.66 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.